Page 40 - 2021_06-Haematologica-web

S. Allali et al.
Disclosures
No conflicts of interest to disclose.
References
Contributions
MM wrote the first draft of the manuscript; SA, MT and JB assisted in writing the manuscript.
1. Quinn CT, Rogers ZR, McCavit Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115(17):3447-3452.
2.Couque N, Girard D, Ducrocq R, et al. Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: impact of national guidelines. Br J Haematol. 2016;173(6):927-937.
3.DeBaun MR. Perspective: thinking beyond survival. Nature. 2014;515(7526):S16.
4.Lubeck D, Agodoa I, Bhakta N, et al. Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease. JAMA Netw Open. 2019;2(11):e1915374.
5. Elmariah H, Garrett ME, De Castro LM, et al. Factors associated with survival in a con- temporary adult sickle cell disease cohort. Am J Hematol. 2014;89(5):530-535.
6.Lanzkron S, Carroll CP, Haywood C Jr. Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Rep. 2013;128(2):110-116.
7. Chaturvedi S, Ghafuri DL, Jordan N, Kassim A, Rodeghier M, DeBaun MR. Clustering of end-organ disease and earlier mortality in adults with sickle cell disease: a retrospec- tive-prospective cohort study. Am J Hematol. 2018;93(9):1153-1160.
8. Habibi A, Ngo S, Audureau E, et al. Causes of death in 198 sickle cell adult patients: old and new trends. Blood. 2019;134(Suppl 1):1031.
9. Adams R, McKie V, Nichols F, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med. 1992;326(9):605-610.
10.Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-895.
11. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288-294.
12.Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-1644.
13.Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hyper- tension, and death in patients with sickle cell disease. Blood. 2006;107(6):2279-2285.
14. Nouraie M, Lee JS, Zhang Y, et al. The rela- tionship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica. 2013;98(3): 464-472.
15. Meier ER, Wright EC, Miller JL. Reticulocytosis and anemia are associated with an increased risk of death and stroke in the newborn cohort of the Cooperative Study of Sickle Cell Disease. Am J Hematol. 2014;89(9):904-906.
16. Habara A, Steinberg MH. Minireview: genetic basis of heterogeneity and severity in
sickle cell disease. Exp Biol Med
(Maywood). 2016;241(7):689-696.
17. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet.
2017;390(10091):311-323.
18. Hebbel RP, Belcher JD, Vercellotti GM. The
multifaceted role of ischemia/reperfusion in sickle cell anemia. J Clin Invest. 2020;130 (3):1062-1072.
19. Gladwin MT, Schechter AN, Ognibene FP, et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation. 2003;107(2):271-278.
20. de Montalembert M, Aggoun Y, Niakate A, Szezepanski I, Bonnet D. Endothelial-depen- dent vasodilation is impaired in children with sickle cell disease. Haematologica. 2007;92(12):1709-1710.
21. Belcher JD, Chen C, Nguyen J, et al. Heme triggers TLR4 signaling leading to endothe- lial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2014;123 (3):377-390.
22. Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999- 2009). Pediatr Blood Cancer. 2013;60(9): 1482-1486.
23. Gladwin MT, Sachdev V. Cardiovascular abnormalities in sickle cell disease. J Am Coll Cardiol. 2012;59(13):1123-1133.
24. Wood KC, Gladwin MT, Straub AC. Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure. Heart. 2020;106(8):562-568.
25.Chaudry RA, Cikes M, Karu T, et al. Paediatric sickle cell disease: pulmonary hypertension but normal vascular resistance. Arch Dis Child. 2011;96(2):131-136.
26. Rosenzweig EB, Abman SH, Adatia I, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diag- nostics and management. Eur Respir J. 2019;53(1):1801916.
27. Cabrita IZ, Mohammed A, Layton M, et al. The association between tricuspid regurgita- tion velocity and 5-year survival in a North West London population of patients with sickle cell disease in the United Kingdom. Br J Haematol. 2013;162(3):400-408.
28. Gladwin MT, Barst RJ, Gibbs JS, et al. Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. PLoS One. 2014;9(7):e99489.
29. Caughey MC, Poole C, Ataga KI, Hinderliter AL. Estimated pulmonary artery systolic pressure and sickle cell disease: a meta- analysis and systematic review. Br J Haematol. 2015;170(3):416-424.
30. Colombatti R, Maschietto N, Varotto E, et al. Pulmonary hypertension in sickle cell dis- ease children under 10 years of age. Br J Haematol. 2010;150(5):601-609.
31. Minniti CP, Sable C, Campbell A, et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell dis- ease: association with hemolysis and hemo- globin oxygen desaturation. Haematologica. 2009;94(3):340-347.
32. Gordeuk VR, Minniti CP, Nouraie M, et al. Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia. Haematologica.
2011;96(1):33-40.
33. Ambrusko SJ, Gunawardena S, Sakara A, et
al. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hyperten- sion in children with sickle cell disease. Pediatr Blood Cancer. 2006;47(7):907-913.
34. Campbell A, Minniti CP, Nouraie M, et al. Prospective evaluation of haemoglobin oxy- gen saturation at rest and after exercise in paediatric sickle cell disease patients. Br J Haematol. 2009;147(3):352-359.
35.Sachdev V, Kato GJ, Gibbs JS, et al. Echocardiographic markers of elevated pul- monary pressure and left ventricular dias- tolic dysfunction are associated with exer- cise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. Circulation. 2011;124(13):1452-1460. Hebson C, New T, Record E, et al. Elevated tricuspid regurgitant velocity as a marker for pulmonary hypertension in children with sickle cell disease: less prevalent and predic- tive than previously thought? J Pediatr Hematol Oncol. 2015;37(2):134-139.
37. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033-1048.
TL,
36.
38.
de Montalembert M, Tshilolo L, Allali S. Sickle cell disease: a comprehensive program of care from birth. Hematology Am Soc Hematol Educ Program. 2019;2019(1):490- 495.
39. Pashankar FD, Carbonella J, Bazzy-Asaad A, Friedman A. Longitudinal follow up of ele- vated pulmonary artery pressures in children with sickle cell disease. Br J Haematol. 2009;144(5):736-741.
40. Alsaied T, Niss O, Powell AW, et al. Diastolic dysfunction is associated with exercise impairment in patients with sickle cell ane- mia. Pediatr Blood Cancer. 2018;65 (8):e27113.
41. Niss O, Fleck R, Makue F, et al. Association between diffuse myocardial fibrosis and diastolic dysfunction in sickle cell anemia. Blood. 2017;130(2):205-213.
42. Pavlu J, Ahmed RE, O'Regan DP, Partridge J, Lefroy DC, Layton DM. Myocardial infarc- tion in sickle-cell disease. Lancet. 2007;369(9557):246.
43. de Montalembert M, Maunoury C, Acar P, Brousse V, Sidi D, Lenoir G. Myocardial ischaemia in children with sickle cell disease. Arch Dis Child. 2004;89(4):359-362.
44. de Montalembert M, Ribeil JA, Brousse V, et al. Cardiac iron overload in chronically trans- fused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome. PLoS One. 2017;12(3):e0172147.
45. Badawy SM, Liem RI, Rigsby CK, Labotka RJ, DeFreitas RA, Thompson AA. Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease. Br J Haematol. 2016;175(4):705-713.
46.Sylvester KP, Patey RA, Milligan P, et al. Pulmonary function abnormalities in chil- dren with sickle cell disease. Thorax. 2004;59(1):67-70.
47.Tassel C, Arnaud C, Kulpa M, et al. Leukocytosis is a risk factor for lung function
1542
haematologica | 2021; 106(6)